7 results about "Brown Adipocyte" patented technology

The present invention aims to provide a novel liver fibrosis inhibiting agent or brown adipocyte activating agent, and a prophylactic and / or therapeutic agent for nonalcoholic steatohepatitis which contains the inhibiting agent or activating agent as an active ingredient. The present invention relates to a liver fibrosis inhibiting agent and a brown adipocyte activating agent, each containing taxifolin as an active ingredient, and a prophylactic and / or therapeutic agent for nonalcoholic steatohepatitis, containing taxifolin as an active ingredient.

The present invention provides a composition having a metabolism-improving action, which comprises a supernatant of brown adipocytes or a purified product thereof. The present invention also provides a method of preparing the supernatant without using a culture solution comprising a high concentration of glucose. The present invention also provides a method of producing brown adipocytes using pluripotent stem cells, which are useful for preparing the supernatant of brown adipocytes. The present invention has succeeded in obtaining a supernatant having a metabolism-improving action from brown adipocytes. It was also possible to obtain the supernatant without using a culture solution comprising a high concentration of glucose. The present invention has also succeeded in producing brown adipocytes from pluripotent stem cells using a feeder-free culture system without adding a cytokine cocktail or the like. The brown adipocyte supernatant of the present invention is expected to be applied to the development of therapeutic agents and cosmetic products for glucose metabolism diseases.

The compounds and methods of the present disclosure exhibit induce Ucp1 transcription, enhance of mitochondrial respiration, activate protein kinase A, increase lipolysis, and increase p38 MAPK phosphorylation in cells, particularly brown adipocytes and white adipocytes. They also protect primary cardiomyocytes against hypertrophy induced by adrenergic agonists. Such compounds and methods are useful in the treatment and prevention of conditions such as obesity and associated complex metabolic, endocrine, and hemodynamic changes, as well as related conditions as dyslipidemias, cardiovascular disease, and type 2 diabetes.

The present application provides a novel medium composition for use in inducing differentiation of somatic cells into brown adipocytes. As the present application, for example, there can be mentioned a medium composition for use in inducing differentiation of somatic cells into brown adipocytes, which is characterized by comprising seven components of a thyroid hormone receptor agonist, a glucocorticoid receptor agonist, a phosphodiesterase inhibitor, insulin, an ascorbic acid derivative, albumin, and an antibiotic. According to the present application, differentiation induction of somatic cells into brown adipocytes can be effectively performed. In addition, according to the present application, brown adipocytes can be effectively maintained.

It is an object of the present invention to provide an anti-obesity composition and an oral administration composition that can promote the gene expression of proteins such as PGC1α and UCP1 that are involved in brown adipocytes and the energy consumption activity of the brown adipocytes, and have the effect of promoting the energy consumption activity in the brown adipocytes. The compositions of the present invention contain a tectorigenin-like substance and pinitol. The tectorigenin-like substance is preferably tectorigenin. The compositions of the present invention can suitably be used as an anti-obesity composition or an oral administration composition.

Provided herein are methods of generating Gata6-positive brown adipose progenitor cells, and brown adipose cells and tissue therefrom. Additionally, provided herein are methods of generating UCP1 positive organoids. Generally, the methods include a step of culturing brown adipose progenitor cells in a medium containing an FGF signaling pathway activator, a BMP signaling pathway activator, a TGFβ activator, a Wnt inhibitor, and a thyroid hormone receptor activator.